Amazon launches a nationwide GLP-1 program through One Medical

Amazon said on April 21, 2026 that its primary care arm, Amazon One Medical, has launched a nationwide GLP-1 management program that folds obesity treatment into routine primary care and connects prescriptions directly to Amazon Pharmacy ^[1][2]. The program uses only FDA-approved, brand-name medications — no compounded GLP-1s ^[3].

The posted prices are the headline. With insurance, Amazon says costs can start as low as $25 a month ^[1][2]. For people paying cash, oral GLP-1s start at $149 a month and injectables — including Wegovy (semaglutide) pens and Eli Lilly's Zepbound (tirzepatide) — start at $299 a month ^[1][2]. Amazon also lists standalone, on-demand prescription renewals at $29 for a message consultation and $49 for a video visit ^[1][2].

The medication menu is unusually broad for a single program. It includes injectable and oral Wegovy, Zepbound in both auto-injector and multi-dose KwikPen form, and Foundayo (orforglipron), Lilly's daily pill ^[2][3]. One review notes Foundayo was approved on April 1, 2026, making Amazon one of the first platforms to offer it inside a clinical program at launch ^[3].

What Amazon says is different

Amazon is framing this as chronic-condition care rather than a one-time prescription. The program includes pre-visit screening, structured consultations, standardized documentation, evidence-based safety protocols and follow-up, with clinicians adjusting blood pressure or diabetes medications as patients lose weight, since GLP-1s can change blood pressure and A1C relatively quickly ^[2]. "Obesity affects more than 40% of U.S. adults, and while advances such as GLP-1-based therapies are helping… without long-term care and clinical guidance, patients can experience negative impacts to their overall health," said Dr. Hemalee Patel, senior medical director of cardiometabolic health at One Medical ^[2].

The logistics piece is the other differentiator. Amazon Pharmacy delivers to all 50 states and offers same-day delivery in nearly 3,000 cities today, with plans to reach 4,500 cities by the end of 2026 ^[1][2]. Manufacturer savings cards from Novo Nordisk and Eli Lilly are applied automatically at checkout, a program Amazon says has saved customers more than $200 million to date, with GLP-1s the largest savings category ^[2]. One Medical also says it has added electronic prior authorization to speed insurance approvals, plus an AI health assistant for navigating appointments and renewals ^[2].

The fine print

Amazon's own announcement and CNBC's coverage describe medication pricing but not the full cost of participating. An independent review published a week after launch reports that new GLP-1 prescriptions require being an existing One Medical primary care patient, and that membership runs about $199 a year for Prime members and about $299 for non-Prime, with the membership fee itself not covered by insurance ^[3]. That same review says the $29–$49 renewal visits write refills only, not new prescriptions ^[3]. Those details are not confirmed in Amazon's press materials as reported by the other sources.

The sources also differ on what "from $149" means over time. CNBC reports oral drugs start at $149 a month ^[1]; the review says oral GLP-1s are $149 at a starter dose and $299 at maintenance ^[3]. Which doses map to which price is not clear from the sources.

Why it matters for patients

For people who have been buying compounded semaglutide or tirzepatide from telehealth sellers, this is another branded-only option with a posted cash price. The review calls $299 a month the lowest injectable cash-pay price among the platforms it tracks, comparing it with NovoCare direct at $349 ^[3] — but adding membership pushes the all-in figure to roughly $316 a month for Prime members ^[3].

Access is uneven. In-person One Medical offices exist in only 20-plus US cities, though virtual care is nationwide ^[3]. Same-day delivery covers about 3,000 cities, not everywhere ^[2]. And because the program launched April 21, 2026, there is no published outcome data on how well it works ^[3]. The program also does not include behavioral coaching, a CBT curriculum or a registered dietitian, according to the review ^[3].

What happens next

Amazon plans to expand same-day prescription delivery to 4,500 cities by the end of 2026 ^[1][2]. Investors reacted immediately: shares of Hims & Hers Health, Viking Therapeutics, Amgen and Septerna fell on the announcement ^[1], with Hims down 6% on the day ^[3].